Sandoz announced today that it has resubmitted to the FDA its Biologics License Application (BLA) for its proposed biosimilar pegfilgrastim.
Sandoz announced today that it has resubmitted to the FDA its Biologics License Application (BLA) for its proposed biosimilar pegfilgrastim.
In July 2016, Sandoz revealed that it had received a Complete Response Letter for the proposed biosimilar, and stated at the time that it was working with the FDA to address the agency’s concerns. The newly resubmitted BLA includes new data from a pivotal pharmacokinetic (PK) and pharmacodynamic (PD) study.
The study was a single-dose, 3-period crossover study that compared the proposed biosimilar with the US-sourced and EU-sourced reference pegfilgrastim, Neulasta, and compared the US- and EU-sourced references.1
In a statement announcing the resubmission, Mark Levick, MD, PhD, global head of development, biopharmaceuticals, Sandoz, said, “The US market is just beginning to benefit from biosimilars, as shown by the success of our filgrastim, the first approved biosimilar in the [United States]. The submission of our pegfilgrastim biosimilar application is another step for us as we continue to lead the way in creating early and expanded patient access to life-changing biologics.”
A previous study in healthy volunteers determined PK similarity, given that the 90% CI for the geometric mean ratio of the biosimilar versus the reference was within the prespecified similarity margin of 0.8-1.25. It also concluded that there was PD similarity between the products, given that the 95% CI for the ratio of the biosimilar versus the reference was within the same prespecified similarity margin.2
The new study was designed to address the high inter-subject variability (ISV) linked to target-mediated clearance with pegfilgrastim; the 3-way crossover design of the new study was intended to address ISV, as well as to provide a bridge between the EU and US reference pegfilgrastim products.
The molecule has also been studied in phase 3 clinical trials in patients undergoing chemotherapy.
Sandoz’s pegfilgrastim biosimilar is already approved in the European Union, where it received a marketing authorization in November 2018 under the name Ziextenzo.
References
1. R Nakov, S Schussler, S Schier-Mumzhiu, et al. A large multi-center, randomized, double-blind, crossover study in healthy volunteers to compare pharmacokinetics and pharmacodynamics of a proposed biosimilar pegfilgrastim with EU and US reference pegfilgrastim: methodological approach. Ann Oncol. 2018;29(8)mdy300.110. doi: 10.1093/annonc/mdy300.110.
2. Nakov R, Gattu S, Wang J, Velinova M, Skerjanec A. Proposed biosimilar pegfilgrastim LA-EP2006 shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects [abstract]. Cancer Res. 2018;78(4):nr P3-14-10. doi: 10.1158/1538-7445.SABCS17-P3-14-10.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.